Head-to-head comparison of everolimus-eluting stents versus zotarolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis

International Journal of Cardiology

Volumn 172, Issue 1, 2014, Pages

  Zhang, Xin Lin ^a   Li, Ran ^a   Wu, Han ^a   Chen, Qin Hua ^a   Li, Guan Nan ^a   Xie, Jun ^a   Xu, Biao ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Everolimus eluting stent; Head to head; Meta analysis; Percutaneous coronary intervention; Zotarolimus eluting stent

Indexed keywords

EVEROLIMUS; ZOTAROLIMUS;

CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; DEVICE SAFETY; DRUG ELUTING STENT; EVEROLIMUS ELUTING STENT; HEART DEATH; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; LETTER; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; STENT THROMBOSIS; TARGET LESION REVASCULARIZATION; TARGET VESSEL REVASCULARIZATION; ZOTAROLIMUS ELUTING STENT;

EVEROLIMUS-ELUTING STENT; HEAD-TO-HEAD; META-ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; ZOTAROLIMUS-ELUTING STENT;

DRUG-ELUTING STENTS; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OBSERVATIONAL STUDY AS TOPIC; PERCUTANEOUS CORONARY INTERVENTION; SIROLIMUS;

EID: 84894104496     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.12.153     Document Type: Article

References (16)

1. M. Pfisterer, H.P. Brunner-La Rocca, and P.T. Buser et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 48 2006 2584 2591
2. G.W. Stone, M. Midei, and W. Newman et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial J Am Med Assoc 299 2008 1903 1913
3. K. Toutouzas, C. Patsa, and E. Tsiamis et al. Everolimus- and zotarolimus-eluting stents for bare metal stent in-stent restenosis treatment: a prospective study J Interv Cardiol 21 2008 388 394
4. C.A. Collet, J.R. Costa Jr., and F. Feres et al. Everolimus-eluting stent versus zotarolimus-eluting stent in the real word clinical practice Rev Bras Cardiol Invasiva 18 2010 400 406
5. J.M. de la Torre Hernandez, F. Alfonso, and F. Gimeno et al. Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Espanol Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2) JACC Cardiovasc Interv 3 2010 911 919
6. J.A. Herrador, J.C. Fernandez, M. Guzman, and V. Aragon Comparison of zotarolimus- versus everolimus-eluting stents in the treatment of coronary bifurcation lesions Catheter Cardiovasc Interv 78 2011 1086 1092
7. G.A. Sgueglia, F. Burzotta, and C. Trani et al. Comparative assessment of mammalian target of rapamycin inhibitor-eluting stents in the treatment of coronary artery bifurcation lesions: the CASTOR-Bifurcation registry Catheter Cardiovasc Interv 77 2011 503 509
8. K.Y. Chen, S.W. Rha, and L. Wang et al. Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: a propensity score-matched analysis JACC Cardiovasc Interv 5 2012 936 945
9. P. Damman, M. Abdel-Wahab, and H. Mollmann et al. Comparison of twelve-month outcomes after percutanous coronary intervention with everolimus-eluting versus zotarolimus-eluting or sirolimus-eluting stents from the PROENCY (PROmus ENdeavor CYpher) registry J Invasive Cardiol 24 2012 495 502
10. E.L. Hannan, Y. Zhong, and C. Wu et al. Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State Catheter Cardiovasc Interv 81 2013 1097 1105
11. N.W. Shammas, G.A. Shammas, and E. Nader et al. Outcomes of patients treated with the everolimus-eluting stent versus the zotarolimus eluting stent in a consecutive cohort of patients at a tertiary medical center Vasc Health Risk Manag 8 2012 205 211
12. M.A. Velders, H. Boden, and B.L. van der Hoeven et al. Long-term outcome of second-generation everolimus-eluting stents and Endeavor zotarolimus-eluting stents in a prospective registry of ST-elevation myocardial infarction patients EuroIntervention 8 2013 1199 1206
13. S.J. Hong Comparison of angiographic and clinical outcomes among patients with sirolimus-, paclitaxel-, zotarolimus-, and everolimus-eluting stent implantation in small coronary target vessels EuroIntervention 8 2012 N66
14. G.K.H. Olivecrona, E. Kedhi, E. Omerovic, S. James, J.G. Smith, and B. Lagerqvist Comparison of drug-eluting stents in real-life clinical practice in Sweden: insights from the SCAAR Register J Am Coll Cardiol 56 2010 B60
15. J.M. Lee, T.J. Youn, and I.Y. Oh et al. Comparison of unrestricted use of resolute zotarolimus-eluting and everolimus-eluting stents: outcomes in a real world setting of coronary intervention in Koreans J Am Coll Cardiol 59 2012 E413
16. S. Bangalore, S. Kumar, and M. Fusaro et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials Circulation 125 2012 2873 2891